GENEMAX CORP. Announces Naked Short Selling Lawsuit Against - 500 Beiträge pro Seite

[morchel]

GENEMAX CORP. Announces Naked Short Selling Lawsuit Against

Broker-Dealers,
Market Makers and Clearing Agents



BLAINE, Wash., Oct. 3 /PRNewswire-FirstCall/ -- GENEMAX CORP. ("the Company") (OTC Bulletin Board: GMXX, Frankfurt: GX1) announced today that it has filed a lawsuit against various broker-dealers, market makers and clearing agents involved in the continued unlawful "Naked Short Sales" of GMXX securities. Named as Defendants in the suit, filed in the U.S. District Court, for the District of Nevada, were:

-- KNIGHT SECURITIES, LP,
-- WM. V. FRANKEL & CO., INC.,
-- CHARLES SCHWAB COMPANY,
-- ICLEARING, LLC,
-- HERZOG HEINE GEDULD,
-- HILL THOMPSON MAGID, L.P.,
-- VFINANCE INVESTMENTS, INC.,
-- AMERITRADE CLEAR,
-- YORKTON SECURITIES,
-- BLACK CORPORATIONS 1-100,
-- DOES 1-100



The suit seeks an injunction to enjoin the unlawful "shorting" activities, and substantial damages, including punitive damages to punish Defendants for their unlawful conduct, which involves, among other things, alleged fraud, negligence, violations of securities laws, racketeering (civil RICO) and conspiracy. If the Company obtains a civil jury verdict for RICO violations, it will be entitled to treble damages from the Defendants.
It is very likely the Company will amend the suit to name additional broker-dealers, market makers and clearing agents, along with individual securities professionals, as soon as trading records can be obtained during the discovery process, or otherwise.

During the past several months, the Company had written letters to the Defendants, as well as other securities professionals involved in GMXX market activities, requesting they voluntarily cease their "Naked Short Sales." Defendants` response to the Company`s request was increased "shorting" activities. Accordingly, the Company was constrained to seek legal remedies in an effort to protect the Company, its shareholders and its business from continued damages and losses caused by Defendants` unlawful conduct.

About GeneMax: GeneMax is a biotechnology company specializing in the discovery and development of immunotherapeutics aimed at the treatment and eradication of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection.


For further information:
Contact: Marcus Johnson
Phone: Toll Free [phone] or [phone] Fax: [phone]
Stock Exchange Information: (Symbol: OTCBB - GMXX, Symbol FWB - GX1,
WKN: 645096, ISN: US36870Q1031)



GENEMAX CORP common stock is traded on the OTC Bulletin Board in the United States under the symbol GMXX and on the Frankfurt Stock Exchange under the symbol GX1.
SAFE HARBOR STATEMENT

THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, THE COMPANY`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN."

[Neono]

Squeeze oder nicht squeeze.
Das ist hier die Frage!





Neono

[miura]

@ morchel und Neono

FYI
http://www.stocklemon.com/articles/08_23_02.html

Jaja ich weiss das sind die "bösen shorties", aber sie
haben in der Vergangenheit Recht behalten... oder nicht ?

Was ist eigentlich aus MDHM geworden mit Ihrem Kampf gegen
die MM ? Auf zockstocks konnt ich nichts darüber finden.

Gruß
miura

[eurogekko]

Morchel it`s a SCAM

[eurogekko]

die haben es selber gemacht!SELBSFERTEIDIGUNG!!wrte ab max. 2 monate und boooom over and out

[eurogekko]

Morchel,$8 oh ja.BIG SCAM.DON`T TOUGH DO NOTHING

[eurogekko]

COMPANY HAS NOTHING ,DIE IR firma hat alles und darum $8.lasst es sein!!!!!!! wer es machen will ....ok leute leute.AUFWACHEN

[eurogekko]

bULL SHIT

[Neono]

Miura
Ich kann mich nicht erinnern, dass aus so einer Sache jemals etwas wurde. Vielleicht bringen die news einen schnellen, aber kurzen Schub nach oben. Von langer Dauer wird es eher nicht sein. Ich lasse die Finger davon!


Neono

[morchel]

Ich hab GMXX von der Watchlist gestrichen! Weil ich schon von zu vielen Seiten höre das es Scam ist!

Ích fand nur die Story interessant!

Der Kampf gegen die Shorter ging auch bei MDMN in die Hose!

Neono hat recht! Gewonnen hat noch keiner. Obwohl sich Shortpositionen über DTC Sheets nachweisen lassen!

morchel

[loss_pro]

warum eigentlich einen lawsuit, gab´s denn schon buy-ins oder sind die S/H nicht kooperativ?

[Javaboy]

Ihr liegt alle total falsch!

GMXX ist KEIN Scam. Der Short-Squeeze ist real. Geht einmal zu Google und schreibt: Dr. Julia Levy. Frau Dr. Julia Levy ist Chairman of the Board von GMXX. Diese Frau ist NICHT in Scam-Deal involviert.

Ich habe schon mitte September hier im Board gesagt, die Aktie ist ein Stron Buy. Und ich bleibe dabei.

[Neono]

Javaboy
Mag ja alles sein, aber ich kenne keine company, die einen solchen Prozess gewonnen hätte. Lass mich gerne eines Besseren belehren!


Good luck!


Neono

[Javaboy]

Neono

Du wirst Dich eines Besseren belehren muessen. Die Firma ist absolut real. Die involvierten Leute (Forscher) sind die Elite von Kanada in diesem Bereich.

[miura]

@ Javaboy,

wenn du dir den Bericht auf Stocklemon einmal durchgelesen
hättest, würdest du zu der Erkenntniss kommen das die
Stocklemon-Leute das gleiche wie du über die Wissenschaftler
sagen.

Die Firma besteht halt nicht nur aus Wissenschaftlern
sondern auch aus Geschäftsleuten. Und diesen Geschäfts-
Leuten geht es in erster Linie um eigenen Profit.

Oder willst du behaupten das Stocklemon lügt ? Dann hätten
die schon längst eine Klage am Hals, gerade bei den amis
geht das ruckzuck.

Gruß
miura

[eurogekko]

@Morchel,geh zu www.stocklemon.com und lese das letzte Filing oct/03/02.Global secur.Union secr. beide Vancouver werden auch verklagt.Morchel es stinkt!!!wird aber interesant!

[Javaboy]

Ich glaube nicht, dass die Leute von Stocklemon luegen. Die Typen von Stocklemon sind Spezialisten im Umdrehen von Tatsachen.

Es scheint mir so, dass Ihr alle keine Ahnung habt wie die Shorterei in den USA ablaeuft. Es gibt "Haeuser" in den USA die sich nur auf das Shorter von Small-Caps spezialisieren. Die ganze Sache ist genau organisiert. Dazu gehoeren unter anderem Internetseiten wie Stocklemon , verlogene Market Makers und vorallem die Bashers in den Chatraeumen. Es ist leider ein riesen Business.

Im Falle von GMXX haben es die Shorters mit den falschen Leuten aufgenommen. Die SEC steht hinter GMXX und nicht den Shortern. Diesen Haeusern muss endlich das Handwerk gelegt werden. Die Politiker und die Oeffentlichkeit in den USA begreifen nur sehr langsam was die Shorter anrichten koennen.

Jeder der diese Aktie geshortet hat wird sehr viel dafuer bezahlen.

[Javaboy]

@Eurgekko

Es ist klar, dass diese beiden Broker eine Gegeklage eingereicht haben. Es ist schliesslich Nordamerika.

Klar stinkt es! Diese beiden Haeuser haben die Hosen gstrichen voll.

[edeka1]

Hallo Javaboy,

jetzt mußt Du aber aufpassen, du läßt Dich gerade mit den
"Spezialisten" vom OTC Board ein.

Was morchel,neono und miura sagen, stimmt immer. Fals es nicht so ist, haben sie tortzdem recht. Ist ganz einfach.

Sie haben langjährige Erfahrung auf dem Gebiet, und keiner weis über die Materie besser bescheid. (Sie glauben es zumindestens)

Also aufpassen.

Gruß edeka1

[miura]

@ edeka1

dann erklär du uns doch bitte mal wie das mit dem shorten
von OTC Aktien abläuft.

So wie bei deiner Lieblingsaktie ?

Gruß
miura

[morchel]

edeka der so viel ahnung vom einzelhandel hat und dadurch auf PBDY setzt! erlich

Die Frage ist nur: Warum zettle ich einen Verfahren gegen MM an wenn ich so einen traumhaften Chart hingelegt habe!

Warum beantragt man kein NASDAQ filing bei einem so hohen Aktienpreis!

Es fehlen die shareholder und die Besitzanteile sind mehr als verschwommen!

Das müsste natürlich vor der NASDAQ aufgelärt werden!

morchel

[loss_pro]

nochmal: warum kein buy-in?

[Neono]

Na endlich meldet sich wieder ein Peabody Fan zu Wort.
Na wie läufts bei eurem Kaffee?
Alle restricted shares schon frei und zum Verkauf bereit?
Noch nicht? Na hoffentlich gibt es dafür noch etwas!





Neono

[Javaboy]

Hi loss_pro

Mit den Lawsuits werden die Buy-ins erzwungen. Die Shorts koennen sich aufgrund der Struktur des Deals gar nicht eindecken.

[loss_pro]

für miura (und alle anderen natürlich auch):

IN THE MONEY: Genemax Battles The Shorts, Who Benefits?

By Steven D. Jones and Carol S. Remond
1,439 words
7 October 2002
11:25
Dow Jones

A Dow Jones Newswires Column

NEW YORK -(Dow Jones)- Try the smell test on this one.

Biotech company GeneMax Corp. (GMXX) volubly protests short sellers
attacking its stock.

But trading restrictions on most GeneMax shares plus legal action by the
company against selected brokerages used by short sellers have enabled
GeneMax to control the float in its stock, or the number of shares free to
trade. The result is that the group with the largest block of tradable
shares is Investors Communication Inc., or ICI, a management firm with close
ties to GeneMax.

As the price of GeneMax has risen to $8 from $4 in early September, ICI has
seen the value of its 580,000 GeneMax shares and 1 million options climb to
more than $12 million. But while most of GeneMax`s founding shareholders are
restricted from trading their shares, ICI is free to exercise and sell its
options.

In an interview Friday, GeneMax director and ICI consultant Grant Atkins
confirmed that ICI held options on 1 million shares and those options could
be exercised at any time, but he said ICI wouldn`t do so. "ICI has a
contract with GeneMax to provide a wide range of services, and it does not
want to have a negative impact on the company," Atkins said.

A pooling agreement locks up 9.1 million of GeneMax`s 15.2 million
outstanding shares. Rule 144 restrictions apply to all but 268,000 shares
that remain free to trade, Atkins said. Nevertheless, 1 million shares of
the stock changed hands in August, or about 52,000 daily. In September,
turnover rose to 1.16 million, or about 56,500 shares daily.

The recent rise in price and volume suggests that short sellers are buying
shares to cover their positions, commonly referred to as a short squeeze.
The only holders with large blocks of stock to sell are insiders. But Atkins
denied any GeneMax insiders were selling, loaning or shorting their shares.

"It`s the shorts," Atkins said. "They are now at the point that they have to
keep going." Atkins termed such trading "manipulation."

Whatever the case, people associated with ICI have in the past had problems
with securities regulators.

Some background: according to Washington state records, Marcus Johnson is
the executive officer of ICI. Johnson is also listed as the contact on
recent GeneMax press releases. Securities filings list Atkins as a
consultant with ICI. Others associated with the management consulting
company include Gino Cicci and Brent Pierce, who is identified in securities
filings as ICI`s president and sole shareholder.

Cicci and Pierce have both had run-ins with securities regulators in British
Columbia, Canada.

In 1995, the B.C. Securities Commission banned Cicci from serving as an
officer or director of a public company for three years in connection with
promotion of a company called DNI Holdings Inc. in Canada.

In 1993, the commission prohibited Pierce from serving as an officer or
director for 15 years. The ruling also stipulated that Pierce cannot serve
as an officer or director of a company "that provides management and
administration, promotion or consulting services to a reporting issuer for a
period of 15 years."

The commission handed down the decision in connection with Pierce`s
directing funds to his personal use from a public offering of shares in
Bu-Max Gold Corp. of Canada.

Atkins said Johnson is the executive officer of ICI and that both Cicci and
Pierce are connected with ICI. "I think they consult to the company."

Common History

GeneMax Pharmaceuticals Inc. was founded in July 1999 as a Delaware
corporation with a wholly owned research subsidiary in British Columbia. The
company licensed a cancer-fighting compound from the University of B.C. and
received a U.S. patent on the compound in April 2002. News of that patent
carried the shares to $10 in early May from 25 cents where they began the
year.

Then several changes took place.

On May 9, a Nevada company named Eduverse.com changed its name to GeneMax
Corp. and announced it was acquiring GeneMax Pharmaceuticals Inc. in a
"share exchange agreement."

Atkins was president of Eduverse.com, which was in the educational software
business until 2001 when it sold all its assets for about $50,000 and
settled $768,000 in other debts by issuing stock. After more reorganization
and a reverse stock split ICI had ownership of 40% of the company, with the
balance held by two individuals and a private company, all of B.C.

As part of the acquisition, the new GeneMax investors and ICI agreed to
"advance" $700,000 to the company. It delivered the first $250,000 on July
18 three days after the acquisition closed.

Most important, the new and old shareholders in GeneMax struck an agreement
that restricted trading on 9.16 million shares, or 95% of GeneMax`s 9.5
million shares. The agreement releases 10% of the shares in July 2003, and
an additional 10% every three months thereafter.

But that lockup didn`t include options in the hands of ICI and other former
Eduverse investors.

On April 5, before its reorganization into GeneMax Corp., the directors of
Eduverse granted 1 million options to ICI exercisable at 50 cents a share
anytime between the date of issue and April 2004. Then on May 9, the same
day the company reorganized into GeneMax Corp., directors of Eduverse
expanded the program to include additional 900,000 options to be offered to
"key personnel" at a price to be set at the time the options were issued.

So far, those options have not been granted to anyone, Atkins said.

Short sellers borrow shares and sell them on the hope of repurchasing the
shares at a lower price in the future and pocketing the difference. Selling
shares short without first borrowing the stock, or naked short selling, is a
riskier practice. While the practice is permitted in the U.S. and Canada,
recent legal challenges cast doubt on the fairness of brokerages that permit
clients to sell millions of shares short, which floods the market with
shares and drives the price down.

GeneMax has attempted to halt short selling in a couple of ways.

On July 30, GeneMax announced that it had amended its by-laws so that it
would recognize transactions backed by paper stock certificates only. Such
"certificate only" or "custody only" transactions flush the naked shorts out
of the market because owners of those shares are unable to produce
certificates.

Last month GeneMax went a step further and sued two Canadian brokers, Global
Securities Corp. and Union Securities Corp., both of Vancouver, B.C. The
action appears to be working.

Pacific International Corp. said last week that it`s not permitting any
short position in GeneMax stock because of the risk of litigation. Octagon
Capital Corp. and Wolverton Securities Ltd., two other Vancouver brokerages
widely used by short sellers, have also reportedly halted shorting GeneMax
shares.

Thursday, GeneMax widened its legal fight with the brokers to U.S. courts
with a suit against 11 U.S. brokerage firms. Filed in U.S. District Court in
Nevada, the suit alleges the brokerage firms engaged in fraud and
racketeering. The suit names Knight Trading Group Inc. (NITE), Charles
Schwab Corp. (SCH) and nine others and seeks injunctions to prevent the
firms from shorting GeneMax shares and unspecified damages.

A spokeswoman for Charles Schwab said the company hadn`t seen the suit yet.
A Knight spokeswoman had no comment.

Both the U.S. and Canadian suits attack the back office by claiming that
brokerages fail to properly close short sales by completing the borrowing
transaction, which results in an illegal secondary offering of shares, the
suits claim.

Art Smolensky, chairman of Global Securities, said GeneMax`s attempt to
impose certificate-only trading has "scarred off" some investors concerned
that the change may soon make the shares illiquid. Now the suits against
brokerages are dampening short selling, too, said Smolensky, whose firm
continues to short the shares for clients. The result is the share price is
moving up, but not because of the fundamentals of the business.

"My hat is off to them," said Smolensky. "This is a novel approach."

With the stock now trading at more than $8, the company has a market

cap of nearly $80 million for what amounts to one unproven cancer

compound, Smolensky added.

-By Steven Jones and Carol Remond; Dow Jones Newswires;

[e-mail]; [e-mail]

[miura]

@ loss_pro

THX

[Javaboy]

Hi Loss_pro

Dieser Artikel ist ein weiterer Beweis wie die Shorter arbeiten. Zum Glueck wird auch dieser Artikel den Leuten die "short" sind nicht helfen.

Javaboy

[morchel]

weiter geht die Story...schon interessant zuzusehen!

http://quote.bloomberg.com/fgcgi.cgi?T=marketsquote99_news.h…

Sollte GMXX die ersten sein die es schaffen den MM den Arsch aufzureissen???

morchel

[Techroad]

Hi Morchel

Ich glaube fest daran, dass GMXX den MM und den Shorties den Arsch aufreissen wird. Der Deal ist "certificate only" und da hilft kein Eindecken ueber den Markt. Shorts koennen nur mit Kaeufen von Certificates eindeckt werden. Es sind allerdings fast keine Certs verfuegbar.

GeneMax is a "certificate only" or "custody only" issuer requiring physical certification of Company ownership for all share transfers. Furthermore, no valid or legally enforceable transfer of GMXX stock can be made through Depository Trust Corporation ("DTC") and/or Canadian Depository For Securities Limited ("CDS") or their nominees. Both DTC and CDS have voluntarily cooperated with the Company to remove GMXX stock from electronic eligibility.

[Javaboy]

GMXX sieht heute recht gut aus. Die Shorters werden sicher versuchen, die Aktie wieder zu druecken. Es wird jedoch von Tag zu Tag enger fuer die Shorties und Market Makers.

Javaboy

[Javaboy]

Hallo Leute

Ich bin sehr gespannt, was diese bei GMXX geschehen wird. Der Kampf zwischen den Short-Sellers und GMXX geht weiter. Die Short-Seller haben meiner Meinung nach sehr schlechte Karten.

Javaboy

[Javaboy]

+18 % auf $7.70

ich bin gespannt, was die Short-Seller heute probieren werden.

[Javaboy]

Hallo Leute

Die $8-Marke wurde durchbrochen. Wahrscheinlich werden die Short-Sellers und die befreundeten Market Makers versuchen den Kurs gegen Handelsschluss zu druecken.

Javaboy

[Javaboy]

Neuer Tag, neues Spiel ...

Die $8-Marke ist bereits wieder durchbrochen.

[Javaboy]

Hallo Leute

Gewisse Leute hier im Board haben die Meinung geaeussert, dass GMXX ein Scam ist. Was sagt Ihr nun zum heutigen Press Release?


GeneMax Corp. Announces Appointment of Dr. Barbara Seliger, Leading Cancer Immunologist, to Its Scientific Advisory Board
Thursday October 31, 9:30 am ET


BLAINE, Wash., Oct. 31 /PRNewswire-FirstCall/ -- GeneMax Corp. (OTC Bulletin Board: GMXX; Frankfurt: GX1) announces today that Professor Dr. Barbara Seliger has joined the Company`s Scientific Advisory Board. Dr. Seliger is Professor of Immunology and Pathophysiology at the Johannes Gutenberg University, Department of Internal Medicine in Mainz, Germany. Dr. Seliger is a world expert in tumor biology, tumor immunology and immunotherapy, including work on TAP (transporters associated with antigen processing), the area of GeneMax`s lead product development, and in HLA class I antigen downregulation in human cancers. She has focused on mechanisms of immune escape, the development of anti-tumor vaccines, immunology and molecular biology of renal cell carcinoma and the identification of tumor-associated antigens as well as novel therapeutic and prognostic markers using proteome-based technologies. Dr. Seliger has published some 80 papers in these areas.


Professor Dr. Seliger said, "I believe that GeneMax`s core technologies involving TAP are entirely innovative and have the potential to alter the course of immunotherapies for tumors and other areas as well. It is a privilege to be involved in this ground breaking work and to help facilitate the upcoming clinical trials."

Dr. Seliger graduated from the Georg August-University in Gottingen in Germany and performed her PhD thesis at the Beatson Institute for Cancer Research, Glasgow, Scotland and the Heinrich-Pette-Institute, Hamburg, Germany. She was post-doctoral fellow at the Max-Planck Institute for Experimental Medicine in Gottingen before she became Assistant Professor for Molecular Biology at the Ludwig Institute and Karolinska Institute in Stockholm, Sweden. In 1990, she was appointed Visiting Professor of Immunology at the Christian Albrechts-University of Kiel, Germany, before she moved to Mainz and granted as a University-Professor at the University of Mainz. In addition, she became a Visiting Professor at the Weizman Institute in Rehovot, Israel and is appointed a Guest Professor at the Karolinska Institute in Stockholm, Sweden. In April 2002, she was offered a Chair for Clinical Immunology at the Martin-Luther University in Halle, Germany. Dr. Seliger is active in different national organizations and is reviewer for more than 15 international journals, including the Cancer Research, International Journal of Cancer, Lancet, The Journal of the National Cancer Institute and Trends in Immunology.

Ronald L. Handford, President & CEO of GeneMax, said, "Dr. Seliger will be a strong addition to our Scientific Advisory Board. Her expertise in our core product development areas, as well as her European presence and international affiliations, will be a significant asset to the company."

Dr. Seliger joins a notable team on the GeneMax Scientific Advisory Board including Dr. Wilfred A. Jefferies, GeneMax`s Chief Scientific Officer and Professor of Biotechnology at the University of British Columbia and inventor of GeneMax`s lead technologies, Dr. Soldano Ferrone, Chairman of the Department of Immunology at the Roswell Park Cancer Institute in Buffalo, New York, Dr. James Hogg, Professor of Pathology at the University of British Columbia, Dr. Victor Ling, Vice President Research at the B.C. Cancer Agency and Dr. Bernard Moss of Bethesda, Maryland, a member of the National Academy of Science and an expert in the field of expression vector systems.

About GeneMax: GeneMax is a biotechnology company specializing in the discovery and development of immunotherapeutics aimed at the treatment and eradication of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection.

Stock Exchange Information: (Symbol: OTCBB - GMXX, Symbol FWB - GX1, WKN: 645096, ISN: US36870Q1031)

SAFE HARBOR STATEMENT

THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, THE COMPANY`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.

Make Your Opinion Count - Click Here




--------------------------------------------------------------------------------
Source: GeneMax Corporation

[Javaboy]

Hallo Leute

Ist erstaunlich ruhig geworden hier im Board. Die Aktie schleicht allerdings weiterhin hoch. Inzwischen sind wir bei $9.16.

Die Spezialisten vom OTC-BB haben offensichtlich auch nichts mehr zu sagen. :-)

[loss_pro]

ich weiß zwar nicht genau, wen du damit meinst, aber es hat sich ja nix geändert, also was soll man neues schreiben?

nur eins zu techroad #29:

lt. der PR vom 23.10. gibt es angeblich nur 265,654 shares im float, aber seitdem wurden exakt 1.012.700 stück gehandelt. d.h. in nur zehn tagen wurde der float ganze 4 mal umgesetzt, also alle GMXX S/H haben theoretisch alle 2 1/2 tage alle ihre shares ge- bzw. verkauft. kann das angehen? wohl nicht.
-können alle S/H von dem aktuellen höhenflug profitieren? nein, da 2/3 keine unterlegten shares im depot haben, also nicht verkaufen können.
-können die shortseller weiter shorten? vermutlich nicht, nicht ohne geliehene shares.
-können die shortseller sich eindecken? aber klar doch, falls sie dies tun "übererfüllen" sie sogar ihr soll: naked verkauft, mit echten shares gecovered, andere sind ja nicht im markt.
bleibt die frage, woher stammen die 1.072.700 shares?
obige erklärung mit dem 4mal hin und her in 10 tagen kann sicher nicht zufriedenstellen.
wer also besitzt 1 mio echte shares?
die freien S/H, so sie denn verkaufen können, nicht, die shortseller ja erst recht nicht.
bleiben das management bzw. die großaktionäre. oder? vielleicht nimmt man es mit angaben in den PRs auch nicht so genau?

[morchel]

....mir bleibt die spucke weg....

morchel

[Javaboy]

Den Shorts bleibt ebenfalls die Spucke weg! $11 im Moment ...

Javaboy

[Javaboy]

Hi loss_pro

Leider verstehst Du den Deal immer noch nicht.

Es sind wirklich nur etwas mehr als 200`000 Aktien im Float.
Die hohen Umsätze sind die Shorters die ihre Positionen immer wieder "flippen". Die Shortseller können ihre Positionen NICHT eindecken. Der Deal GMXX ist "certificates only". Die Shortseller können demzufolge ihre Shortpositionen nicht über den Kauf von Shares im Markt eindecken. Der einzige Ort Zertifikate zu kriegen ist bei der Firma selber.

Ich habe hier im Board immer gesagt, dass GMXX ein strong buy ist. Ich bleibe weiterhin dabei. Der Shortsqueeze ist bald da. Es ist Zeit, dass die Shortseller für alles bezahlen was sie vielen Investoren angetan haben.

[loss_pro]

okay, erklär´s mir nochmal; wie schieben die shorties ihre negative position hin und her, wenn nur mit den zertifikaten gehandelt werden kann (die die shortseller ja nicht haben)?
und wieso sollten sie den preis hochschaukeln, was ja bei einer shortposition contraproduktiv ist?
und warum behauptest du damit das krasse gegenteil zu #33und #30, wo du ja meinst, die shorties würden den preis drücken wollen?
.
.
.
.

[eurogekko]

@loss_pro Fuer Unwissende sieht der Stock natuerlich super aus ( $11 US),aber warte ab ,der grosse Bing Bang kommt frueher oder spaeter!Wird wie eine soap opra.Best Eurogekko

[loss_pro]

Martinez-Ayme Securities Initiates Coverage On GeneMax Corp. (GMXX) With A Sell Recommendation
PR Newswire - November 07, 2002 09:31

MIAMI, Nov. 7 /PRNewswire/ -- Martinez-Ayme Securities, a Member of the National Association of Securities Dealers CRD #109838, today released its research report on GeneMax Corp. (OTC Bulletin Board: GMXX) with a sell recommendation in a 3 page research report entitled "Fundamentals Do Not Support Current Valuation; Buyers Beware."

12 MONTH PRICE OBJECTIVE: $2.00 RECENT PRICE: $12.35 PER SHARE
OTC BB: GMXX MARKET CAP: $188,000,000
CAPITALIZATION: AUGUST 2002 COMMON STOCK: 15,160,119 SHARES
RECOMMENDATION: STRONG SELL/FUNDAMENTALS DO NOT SUPPORT CURRENT
EVALUATION
RISK RATING: EXTREMELY SPECULATIVE 52 WEEK RANGE: $12.35 TO $0.15
NINE MONTHS ENDING: Sep, 30 2002 NET SALES: $0.00 NET EARNINGS: $0.00
RECOMMENDATION: SELL 30 DAY AVERAGE VOLUME: 113,582

GeneMax Corp., a Nevada corporation and formerly known as "Eduverse.com" currently trades on the OTC Bulletin Board under the symbol "GMXX" and on the Frankfurt Stock Exchange under the symbol "GX1". The Company has commenced the closing of the acquisition of GeneMax Pharmaceuticals Inc. ("Eduverse.com"); the shareholders of GeneMax Pharmaceuticals and Investor Communications International, Inc., a Washington corporation ("ICI") entered into a share exchange agreement.

GeneMax Pharmaceuticals was formed in Delaware during 1999, and its British Columbia, Canada subsidiary was formed in 2000. GeneMax Pharmaceuticals is a biotechnology company specializing in the discovery and development of immuntherapeutics aimed at the treatment and eradication of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection. Management of the Company believes that the global market for effective cancer treatments is large, and that immunotherapies representing potential treatments for metastatic cancer are an unmet need in the area of oncology.

GeneMax has had a meteoric rise in price over a quick period of time, reflecting very favorable publicity from Internet investment advisories, which received cash compensation from ICI. Martinez-Ayme Securities is unaware of any fundamental news to justify these inflated prices. We believe that there will be no clinical data available until phase 1 of the clinical trial is completed which will take at least 2 years. The company issued approximately 2.7 million shares in a private placement in May and June ranging in prices as low as $.0125 a share. The total of over 2.7 million issued represents over a 15% dilution. The company`s shares at current price levels have a market capitalization of approximately $200 million. Despite positive market interest in biotech, and pharmaceuticals industry forecasts for the "cure of cancer" the shares can move lower on current weak fundamentals. Martinez-Ayme Securities believes GMXX shares should not be purchased at this time, but are rather a candidate to be sold since the production plans have to go through many years of clinical trials before they can actually get the TAP therapy into production and distribution worldwide and are at least about 18 months away from beginning clinical trials. They will have to go through three phases of clinical trials: Phase 1 and Phase 2 -- each lasting about a year; Phase 3, which involves many clinical sites and lots of doctors and hundreds of patients, presumably some in Europe, North America and Japan. Before they can try this approach in humans, the Food & Drug Administration wants proof that it is safe to insert the gene; as a result we believe the stock is exceedingly overvalued.

The Product -- GeneMax has a patent position on the two technologies they are licensed in. They have U.S. Patents and other European and Japanese coverage as well. GeneMax lead product compound, which is the TAP, was given an allowance from the U.S. Patent Office for the use of a TAP-1 gene against all cancers in the fall of 2000. In the spring of 2002, GeneMax was finally awarded a patent. The history of development of this was many years in the making -- it was 1994 that the University of B.C. had first applied for this patent and it took many years of laboratory testing to prove that the technology worked not just with a small cell lung cancer cell line in mice but establishing that it worked also with a melanoma and prostate cancer cell line, and it is with all of the data that they were finally awarded a very broad patent for the use of their TAP-1 gene against all cancers.

GeneMax also has a second product. It is called Peptide Transfer Assay and this also has a U.S. Patent issued on it. Basically, this is a related topic to GeneMax`s lead candidate in that it`s a tool by which they can assess compounds for their ability to modulate the immune system. For example, they can screen through hundreds of compounds, whether they be natural products or man-made chemical libraries, or genes, or anti-sense compounds, and determine if any of these compounds have the ability to boost or suppress this antigen presentation -- in other words if they`re modulating the immune system. For example, if GeneMax finds drug candidates, which suppress the immune system, this would be good for applications in autoimmune diseases or transplant surgery. On the other hand, if GeneMax found things that boost the immune system, this would be very good for cancer or viral applications.

FINANCE -- Management of the Company believes that an estimated $15,000,000 is required over the next three years for payment of expenses associated with the balance of pre-clinical development and commencement of phase I clinical trials for the TAP Technology and for corporate expenses. Company claims it is working on long-term financing, some of which was supposed to be completed in mid-September but to date there has been no announcement of any financing.

MANAGEMENT -- The present management has diversified experience, but there is no evidence that management has any ability in the area.

CONCLUSION -- The wild price action appears to indicate a promoted and inflated stock under which a thin float was utilized to spur a huge run-up in the stock price and it may subsequently decline. We believe the price of the shares may collapse under the selling wave projected by reality. The production plans have to go through many years of clinical trials before they can actually get to the TAP therapy into production and distribution worldwide and are at least about 18 months away from beginning clinical trials and then they will have to go through three phases of clinical trials: Phase 1 and 2 each lasting about a year; Phase 3 which involves many clinical sites and lots of doctors and hundreds of patients, presumably some in Europe, some in North America, some in Japan. This will take GMXX at least another two years so the earliest they are going to be in production is about 51/2 years.

ALL INVESTMENTS INVOLVE RISK. THE RISK INHERENT IN A PARTICULAR SECURITY MAY NOT BE APPROPRIATE FOR YOU. PLEASE CONSULT WITH YOUR MARTINEZ-AYME SECURITIES EXECUTIVE TO OBTAIN ASSISTANCE IN SELECTING APPROPRIATE INVESTMENTS. THIS REPORT IS PUBLISHED FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS AN OFFER OR THE SOLICITATION OF AN OFFER TO BUY OR SELL THE SECURITY. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES THAT THE COMPANY BELIEVES TO BE RELIABLE BUT THE COMPANY MAKES NO GUARANTEE OR REPRESENTATION ABOUT THE COMPLETENESS OF THE STATEMENTS OR SUMMARIES OF AVAILABLE DATA CONTAINED HEREIN. THIS INFORMATION IS PROVIDED AS OF THE DATE OF THIS REPORT, AND IS SUBJECT TO CHANGE WITHOUT NOTICE. FURTHERMORE, THE INFORMATION IN THIS REPORT SHOULD BE CONSIDERED OUTDATED 90 DAYS AFTER PUBLICATION, OR SUCH EARLIER DATE AS CIRCUMSTANCES MAY REQUIRE, AND SHOULD NOT BE RELIED UPON THERE AFTER TO DEVELOP INVESTMENT STRATEGIES. MARTINEZ-AYME DOES NOT CURRENTLY MAKE A MARKET IN THE SECURITIES OF GENEMAX CORP. AT TIMES IN THE PAST WE HAVE MADE A MARKET IN THESE SECURITIES. NOR DOES MARTINEZ-AYME SECURITIES OR ANY OF ITS PRINCIPALS, MAINTAIN A LONG OR SHORT POSITION IN GENEMAX CORP.

Contact: Martinez-Ayme Securities
Reynaldo A. Martinez
305-271-3232
E-mail [e-mail]
http://www.martinezayme.com

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X58956982

SOURCE Martinez-Ayme Securities,

/CONTACT: Reynaldo A. Martinez, Martinez-Ayme Securities,
[phone], or e-mail, [e-mail]/

/Web site: http://www.martinezayme.com/

(GMXX)

[Javaboy]

Dieser Research Report ist wahrscheinlich der letzte Strohhalm an dem sich die Shortseller noch halten können.

[huconcept]

Ich habe heute von einem für die Drillisch AG als externen Berater tätigen Person, die Nachricht erhalten, daß dieses
Unternehmen nicht von der Quam übernommen wird, sondern
Quam mit der T-Mobil eine Vereinbarung getroffen hat, seine
Vertraglichen ansprüche bzw. Verpflichtungen gegen die Großaktionäre der Drillisch AG an die T-Mobil weitergereicht zu haben, mit einer Zahlung (Zahlungshöhe mir nicht bekannt).Mein Bekannter hat noch zusätzlich mitbekommen, das in den oberen Etagen des Unternehmens,
diese Problematik rechtlich überprüft wird, ob man diese
Nachricht bei der Hauptversammlung den Aktionären mitteilt.
Er meint aber da Drillisch wirklich jetzt von der T-Mobil
übernommen wird und automatisch die freien Aktionäre davon
betroffen wären(Pflichtangebot von T-Online an die restlichen Aktionäre),wird das Unternehmen während der Hauptversammlung dieses auch mitteilen, auch den Übernahme Preis.
Er hat mir keinen Übernahme Preis mir genannt, aber mir mitgeteilt, das dieses um ein vielfaches des Kurses von heute von 1,14 bis 1,16 sein wird.

[huconcept]

Ich habe heute von einem für die Drillisch AG als externen Berater tätigen Person, die Nachricht erhalten, daß dieses
Unternehmen nicht von der Quam übernommen wird, sondern
Quam mit der T-Mobil eine Vereinbarung getroffen hat, seine
Vertraglichen ansprüche bzw. Verpflichtungen gegen die Großaktionäre der Drillisch AG an die T-Mobil weitergereicht zu haben, mit einer Zahlung (Zahlungshöhe mir nicht bekannt).Mein Bekannter hat noch zusätzlich mitbekommen, das in den oberen Etagen des Unternehmens,
diese Problematik rechtlich überprüft wird, ob man diese
Nachricht bei der Hauptversammlung den Aktionären mitteilt.
Er meint aber da Drillisch wirklich jetzt von der T-Mobil
übernommen wird und automatisch die freien Aktionäre davon
betroffen wären(Pflichtangebot von T-Online an die restlichen Aktionäre),wird das Unternehmen während der Hauptversammlung dieses auch mitteilen, auch den Übernahme Preis.
Er hat mir keinen Übernahme Preis mir genannt, aber mir mitgeteilt, das dieses um ein vielfaches des Kurses von heute von 1,14 bis 1,16 sein wird.

[Javaboy]

Hallo Leute!

Die Short-Sellers haben es wieder einmal versucht die Aktie zu drücken. GMXX hat trotzdem mit plus $0.40 auf $11.80 geschlossen.

Ich wünsche allen ein schönes Wochenende.

[morchel]

....dennoch ist die MK übertrieben hoch!

Sorry javaboy, aber so ist es!

morchel

[Javaboy]

Hi Morchel!

Mag ja sein. Wenn die Short-Seller eine Aktie runter shorten sagt ja auch keiner die MK ist sehr tief.

Es ist Zeit, dass die Short-Seller auch einmal bezahlen! Nicht immer die armen Investoren.

Javaboy

[morchel]

in dem Punkt stimme ich mit dir überein!

Aber ich sehe das ganze als einen Short squeeze der in die Länge gezogen ist....also irgendwie ein long squeeze!

Nur wen die Decke erreicht ist, dann sollte man am besten schon draussen sein!

morchel

[Javaboy]

Hallo Leute

Ich haben einen Artikel im Business Week Online über GeneMax gefunden.

Sollte jemand den Artikel als PDF-File sehen wollen bitte schreibt mir ein e-mail an [e-mail]


November 11, 2002

Developments to Watch
Edited by Otis Port

Waking Up a Sleeping Anticancer Gene

When cells turn malignant, the immune system can often spot and kill them before they grow into tumors. But this sentinel system fails far too often. Geneticist and immunologist Wilfred A. Jefferies at the University of British Columbia wanted to know why. Searching for genes that are turned on and off in cancer cells, he discovered that a crucial gene is silenced in more than half of tumors--and in virtually all metastatic cancers. Its role: making a protein, dubbed TAP, that performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells.

If he added an active version of the gene to tumor cells, Jefferies wondered, would the immune system then attack the cancer? His experiments in mice show that the answer is yes. When he used a modified virus to carry the TAP gene into mice with extensive small-cell lung tumors, 30% of the mice were cured. The rest showed no metastasis and lived twice as long as those without the gene.

Before Jefferies can try this approach in humans, the Food & Drug Administration wants proof it is safe to insert the gene. Jefferies, now chief science officer of startup GeneMax Corp. (.GMXX ) in Blaine, Wash., believes the company should be able to answer the safety questions and start clinical trials in melanoma patients within 18 months. In a forthcoming paper, he will also present data showing that adding the TAP protein can bolster the immune response to infectious agents such as HIV and smallpox.
By John Carey

[Morgagelchel]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Javaboy]

Die $12-Hürde wurde gestern wieder "genommen". Ich höre weiterhin, dass die Short-Sellers ins Teufels Küche sind. Es bleibt weiterhin spannend.

[Javaboy]

Hallo Leute

Squeeeeeeeeeeeeeeeezzzzzzzzzzzzeee. $15.5! Bin gespannt wo wir schliessen werden.

[morchel]

hätte ich nicht für möglich gehalten! Ist aber schön zuzuschauen!

Level2 siehr IMHO sehr gut aus!

morchel

[loss_pro]

na, morchel auch wieder in RMEC?
siehe news von gerade eben.

[morchel]

Ein paar Prozente hab ich mitgenommen, war aber nicht der Rede wert!

GMXX stürmt von einen High zum anderen! Schon gewaltig was man machen kann wenn der Folat unter Kontrolle ist!

Die Mk ist eigentlich nicht mehr angemessen!

Schaut aus als ob sich die MM zumindest nicht mehr trauen weiter short zu gehen!

morchel

[Javaboy]

Hi Morchel

$18.25!!!

Mach Dir keine Gedanken betreffend MK. Die Short-Seller bezahlen jetzt endlich einmal. Das ist erst der Anfang vom Ende für gewisse Short-Seller.

Javaboy

[Neono]

Herzlichen Glückwunsch Javaboy!
Hätte niemals daran geglaubt und auch heute noch nicht, aber der Kurs gibt dir Recht.





Neono

[morchel]

Es ist eine Genugtuung und ein Mahnmal für die Shorter!

Auf das habe ich schon immer gewartet!

Wenn die Reise auch ohne mich geht....es gefällt mir!

morchel

[morchel]

Tageschart:



morchel

[morchel]

Freunde, wo is die Decke?

Ich dachte immer wenns gut geht ists bei 10 aus! Dann 12, 15, 17, jetzt will das ding über 19 gehen!


guter Gott....

morchel

[Javaboy]

Hi Morchel

Ich habe gehört, dass es bis $30 gehen könnte. Wir werden sehen ....

[Javaboy]

Schlusskurs gestern $18.80. Die Probleme der Short-Seller werden jeden Tag grösser.

[Javaboy]

Hallo Leute!

Was für ein wilder Kursverlauf gestern. Nachdem wir einmal kurz über $20 waren, ging es ziemlich tief runter. Schlusskurs bei $14.65. Die Aktie wird meiner Meinung nach weiterhin sehr nervös bleiben. An der Tatsache, dass sich eine riesige Short-Position im Markt befindet hat sich allerdings nichts verändert. Es bleibt weiter spannend.

[loss_pro]

haste wenigstens verkauft? sieht charttechnisch überhaupt nicht mehr gut aus. close auf day-low

[Javaboy]

Hallo loss_pro!

Ja, ich habe verkauft. Ich führe allerdings zwei Positionen. Eine Long-Position und eine Position mit der ich ganz einfach "trade". Diese Aktie ist im Moment fantastisch zum Traden.

[loss_pro]

na, nich gerade konsequent, aber wir haben ja alle unser trading macken

[SteveBiko]

Ich habe gehört, dass sich heute einer der Grossaktionäre aus der Aktie verabschiedet hat. Seiner Meinung nach ist sie überbewertet. Daher ein wenig Vorsicht

Remember Steve

[Javaboy]

Wir werden sehen, was diese Woche bringt. Es ist klar, dass GeneMax im Moment stolz berwertet ist. Es ändert allerdings weiterhin nichts an der Tatsache, dass die Shortpositionen weiterhin bestehen. Die Eindeckung dieser Positionen muss früher oder später erfolgen.

[Javaboy]

Die Party scheint wieder loszugehen. Ich bin gespannt wohin diesmal die Reise geht. > $20? Wir werden sehen. Die Shortpositionen sind auf jeden Fall weiterhin vorhanden.

Javaboy

[loss_pro]

du mußt es ja wissen...

[gegosi]

... geht glaub wieder los !

[Javaboy]

GeneMax Corp. Announces Appointments of Dr. Wilfred Jefferies as Chairman of the Board of Directors, Dr. Julia Levy as Chair of the Scientific Advisory Board, and Dr. Karl Erik Hellstrom, Leading Cancer Immunologist, to the Board of Directors



BLAINE, Wash., Dec. 9 /PRNewswire-FirstCall/ -- GeneMax Corp. (OTC Bulletin Board: GMXX, Frankfurt: GX1) announces today that Dr. Wilfred Jefferies has been appointed Chairman of the Board of Directors, in addition to his role as Chief Scientific Officer. Dr. Julia Levy has been appointed Chair of the Company`s Scientific Advisory Board, which will guide clinical trials, scientific development as well as making recommendations to the Board of Directors. The appointment of Dr. Jefferies to Chairman of the Board recognizes his position as the vision and drive behind the technological development of GeneMax. Dr. Karl Erik Hellstrom joined the Board of Directors concurrently with these appointments.
ADVERTISEMENT


Dr. Levy said, "While I am seeking to reduce significantly my director appointments and corporate activities generally, I believe Dr. Jefferies` work in the area of cancer immunotherapies is truly compelling and I look forward to chairing the GeneMax Scientific Advisory Board to help guide the rapid development of TAP-related products into clinical trials. The Scientific Advisory Board appointment allows me to concentrate on GeneMax`s scientific development without the increasing time commitment required as a GeneMax director."

Dr. Karl Erik Hellstrom received his M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden, initially working in the area of tumor biology with an emphasis on immunogenetics. As a student of Dr. George Klein, he was a member of the team that showed, for the first time, a tumor-destructive immune response to an animal`s own, autologous tumor. After being recruited to the faculty of the University of Washington Medical School (Professor in Pathology with an adjunct Professorship in Microbiology/Immunology), in 1966, Karl Erik Hellstrom, and his wife, Dr. Ingegerd Hellstrom, became internationally known after they reported that there is a T- lymphocyte-mediated immune response to human tumors, a discovery that opened new avenues for research and development of cancer therapy. Subsequently their team discovered some of the first monoclonal antibodies to antigens expressed by human tumors, and they were among the first to publish on the utility of such antigens as possible targets for antibody-mediated cancer therapy via drug conjugates, immunotoxins, or antibodies alone. In addition to having authored some 440 papers and been awarded many US and foreign patents, Karl Erik Hellstrom has, together with his wife, contributed to science by training a number of graduate students and postdoctorals, several of whom went on to leading positions in academia or industry.

He moved in 1975 to the newly established Fred Hutchinson Cancer Research Center in Seattle as Director of its Tumor Immunology Program. In 1983, he joined the then founded biotechnology company Oncogen which, in 1990, was integrated into the Pharmaceutical Research Institute of the Bristol-Myers Squibb Company. Dr. Hellstrom became Vice President, first of the Oncology Discovery and, since 1995, of Immunotherapeutics. In the Fall of 1997 Dr. Hellstrom moved from Bristol-Myers Squibb to Pacific Northwest Research Institute, where he, together with Dr. Ingegerd Hellstrom, is leading a group in Tumor Immunology as a Principal Investigator. He retains an Affiliate Professorship at the University where he sometimes teaches. Dr. Hellstrom has been a past member of two NIH Study Sections (Immunobiology and Experimental Immunology), and of the Scientific Advisory Board of Memorial Sloan Kettering Institute for Cancer Research as well as of the Scientific Advisory Board of Hybritech Inc. He has received many awards, including the Parke-Davis award in experimental pathology, Alpha Omega Alpha, the Lucy Wortham James award of the Ewing Society, the Pap Award for outstanding contribution to cancer research; the Humboldt Award to a senior U.S. scientist; and the yearly American Cancer Society National Award. He has also been honored as Knight of the Northern Star, First Class, Swedish Order of Merit.

Dr. Hellstrom said, "I feel that the science of GeneMax is outstanding with lots of promise towards development of marketable products and I am very much looking forward to working with the Board of Directors, the Scientific Advisory Board and development team at GeneMax."

Ronald L. Handford, President & CEO of GeneMax, said, "With the appointments announced today we have now built a formidable Board and Scientific Advisory Board. Dr. Jefferies is passionate about using his innovative technology and ideas to treat human diseases, and he is equally ardent about corporate governance issues and the responsibilities of the Board to all stakeholders in the Company. Dr. Julia Levy will continue to bring her excellent judgment in technology assessment, corporate development, clinical trials and commercialization to bear on GeneMax. Dr. Hellstrom`s background as a senior product discovery officer in a large pharmaceutical company, his belief in the strong prospects for our cancer vaccine approach, and his world-wide contacts in industry, academia and finance related to biotechnology will be a tremendous asset to our Board."

About GeneMax: GeneMax is a biotechnology company specializing in the discovery and development of immunotherapeutics aimed at the treatment and eradication of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection.

Stock Exchange Information:
(Symbol: OTCBB - GMXX, Symbol FWB - GX1, WKN: 645096, ISN: US36870Q1031)


SAFE HARBOR STATEMENT

THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, THE COMPANY`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.




--------------------------------------------------------------------------------
Source: GeneMax Corp.

[Javaboy]

GeneMax broadens Global, Union suit to name brokers

2002-12-31 09:00 - Street Wire.

by Brent Mudry

GeneMax, a tiny biotechnology penny stock promotion at the centre of a controversial and well publicized short squeeze, is trying to up the ante in its naked-shorting market manipulation suit against two Vancouver brokerages, Global Securities and Union Securities. In a recent brief hearing in the Supreme Court of British Columbia, GeneMax added seven brokers at the Vancouver houses, including Global founder and head Art Smolensky, as defendants.

The new defendants includes Global`s Mr. Smolensky, Carol Ann Zosiak, Daniel Caamano and Blair Alan Bigwood, and Union brokers John Cameron Gardner, Karl Harry Landra and Peter James Irvine. The amended statement of claim, filed in draft form on Nov. 15 and officially rubber-stamped Dec. 12 by Master Patterson, also names unidentified "John or Jane Doe 1-10.) "GeneMax anticipates that the defendants John or Jane Doe 1-10 will include other stockbrokers and short sellers trading in GeneMax shares," states the amended suit.

The amended B.C. suit is the latest court development in the short life of GeneMax, which began trading July 15 at $6 on the OTC Bulletin Board after a reverse takeover of Eduverse.com, one of the penny shells in the stable of controversial Howe Street promoter Brent Pierce and his long-time associate Grant Atkins. (All figures are in U.S. dollars.) After months of negative publicity, including Stockwatch`s Sept. 12 note of Mr. Pierce`s involvement, QLT Inc. founder Dr. Julia Levy, a respected Vancouver biotechnology figure, finally resigned as chairwoman of GeneMax on Dec. 12. (There is no allegation of any wrongdoing on the part of Dr. Levy.)

In an eye-opener in the penny stock world, GeneMax was launched with certificate-only transfer, disallowing electronic share transfers. Shorts that may have been attracted by Mr. Pierce`s reputation seemingly missed the razor-thin float of 265,654 free-trading shares as of Aug. 2. The short position swelled to at least 714,000 shares by mid-October. Amid a short squeeze, GeneMax shares briefly peaked at $20.40 on Nov. 14. The stock closed at $5.75 on Monday.

GeneMax sued Global and Union on Sept. 4, claiming that naked shorting by the brokerages and its clients constituted a market manipulation scheme. The brokerages deny the allegations, and launched counterclaims. While Vancouver lawyer Paul Miller of Boughton Peterson Yang Anderson filed the original suit, GeneMax later switched lawyers a few weeks later, and is now represented, since Oct. 10, by Elizabeth Liu of Basham Thompson & Liu, a smaller law firm.

[gegosi]

GMXX:

http://biz.yahoo.com/prnews/030116/sfth046_1.html

[Javaboy]

Hallo zusammen!

Ich habe mir wieder ein paar Aktien ins Depot gelegt. Es geht bald wieder los. Ich hoffe, die Short-Sellers werden endlich den Preis bezahlen.

Javaboy

[eurogekko]

Wer in diesen Tagen nen OTC BB stock bei $7 kauft dehm kann man nicht helfen !!Speziel GMXX und die anderen Buden,die mit der Truppe zusammen haengt!Alles Gute

[eurogekko]

Javaboy: Es kann der Tag kommen und alles ist vorbei!!bang,suspendet ,pinks, 0,007.Die Jungs lehnen sich zuweit aus dehm fenster

[Javaboy]

Eurogekko: Genau darum erschien in den USA auf ABC ein Interview mit den Forschern von GeneMax.

http://www.genemax.com

[gegosi]

schaut Euch das mal an:

http://modena.intergate.ca/personal/jks/

[gegosi]

... mit neuen INFOS.
... mit Musik. Webpage & Aktien-Kurs.


http://modena.intergate.ca/personal/jks/

[gegosi]

Die MUSIK ist SUPER.
Fundamentals auch.

http://biz.yahoo.com/prnews/030228/sff004_1.html